linjc16/ctgov huggingface dataset:
Genetic Analysis of Gray Platelet Syndrome

Study Overview
=================
Brief Summary
-----------------
This study will identify and characterize the gene or genes responsible for Gray Platelet syndrome (GPS). Platelets are small blood cells that stick on injured blood vessels to form a plug and stop bleeding. When a blood vessel is injured (like a cut on a finger), platelets release the proteins stored in their sacs to help form a blood clot. Patients with GPS bleed longer than other people because their platelets lack some of these protein-carrying sacs. Platelets without sacs look pale gray under the microscope rather than pink, giving the syndrome its name. Except for rare patients with severe hemorrhage, the bleeding tendency in GPS is usually mild to moderate, with patients experiencing easy bruising, nosebleeds, and, in women, excessive menstrual bleeding. Patients with GPS and members of their family with GPS may be eligible for this study. Participants will provide a personal and family medical history and will have blood drawn. About 1 to 2 tablespoons of blood will be drawn in adults, and about 1 teaspoon in children. The blood will be analyzed for genes that cause GPS

Detailed Description
-----------------
Patients with Gray Platelet Syndrome (GPS) and their unaffected family members will be studied to identify the gene(s) involved in GPS using linkage analysis and gene mapping strategies. Up to 200 individual members of GPS families will be investigated to identify candidate regions of the human genome, which will be further studied using fine mapping and sequence analysis. Characterization of gene(s) involved in GPS could provide important insight into the mechanisms of vesicle formation and protein sorting in human cells.

Official Title
-----------------
Genetic Analysis of Gray Platelet Syndrome

Conditions
-----------------
Genetic Linkage, Myelofibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Enrollment in this study will be limited to patients diagnosed with GPS and their unaffected relatives. The diagnosis will be based upon absence or marked reduction of platelet Alpha-granules on electron microscopy. EXCLUSION CRITERIA: Patients with reduction in both Alpha and Beta granules will be excluded, since this is probably a separate disease.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gene Identification, Linkage Analysis, Homozygosity Mapping, Gray Platelet Syndrome, GPS, Platelet Function Defect, Bleeding Disorder
Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection

Study Overview
=================
Brief Summary
-----------------
The study was not opened.

Official Title
-----------------
Evaluation of Whole Blood Samples From Coronavirus Disease 2019 (COVID-19) Convalescent Patients to Study Immune Response and Severity of Disease Predictors

Conditions
-----------------
COVID, Sars-CoV2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have previously been diagnosed with COVID-19 but are now asymptomatic >14 days and a matched number of healthy controls: Consent: Subject able to provide voluntary written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. SARS-CoV-2 Testing Status: Experimental Population: Subject has had positive SARS-CoV-2 verified by clinical laboratory OR Control Population: Subject without testing or negative SARS-CoV-2 testing Complete resolution and current absence of clinical symptoms Symptoms Defined as: Fever, Dry cough, Fatigue, Difficulty breathing, Sore throat, Diarrhea, Rhinorrhea (runny nose), or new aches/pains. Age: Greater or equal to 18 years of age. a. Subject must be able to provide voluntary written consent Exclusion Criteria: Ongoing symptoms of COVID19 due to SARS-CoV-2 infection a. Symptoms Defined as: Fever, Dry cough, Fatigue, Difficulty breathing, Sore throat, Diarrhea, Rhinorrhea (runny nose), or new aches/pains. Ongoing symptoms not due or not known to be due to SARS-CoV-2 infection a. Symptoms Defined as: Fever, Dry cough, Fatigue, Difficulty breathing, Sore throat, Diarrhea, Rhinorrhea (runny nose), or new aches/pains. Patients receiving ongoing medical symptomatic treatment or prophylaxis treatment related to COVID-19 due to SARS-CoV-2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Convalescent subjects<br>Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection | |
| Healthy controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of specific T cell responses in peripheral blood isolated from patients that have been exposed to SARS-CoV-2. |  | Up to 1 year post infection. |
Portal Vein Flow Velocity as a Screening Tool for Oesophageal Varices in Cirrhotic Patients

Study Overview
=================
Brief Summary
-----------------
Portal vein flow velocity as screening tool for prediction of oesophageal varices in cirrhotic patient without upper endoscopy

Detailed Description
-----------------
Portal vein flow velocity as screening tool for prediction of oesophageal varices in cirrhotic patient without upper endoscopy with its high cost & complications Using portal vein flow velocity and the relation between it & presence of oesophageal varices in cirrhotic patient & its efficacy as a primary tool for these cases

Official Title
-----------------
Portal Vein Flow Velocity as a Screening Tool for Oesophageal Varices in Cirrhotic Patients

Conditions
-----------------
Cirrhosis Portal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cirrhotic patients with oesophageal varices cirrhotic patients without oesophageal varices Exclusion Criteria: Patients with hepato-cellular carcinomas [HCCs], portal vein thrombosis, hepatic encephalopathy. Patients with positive HCV antibody, but without liver cirrhosis diagnostic criteria
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Using upper GIT endoscopy to detect the presence or absence of oesophageal varices | Non-invasive screening tool for esophageal varices: Aspartate aminotransferase-to-platelet ratio index (APRI) ... Doppler ultrasound of portal system Elastography both of liver and spleen... -Research outcome measures: a. Primary (main): Using upper GIT endoscopy to detect the presence or absence of oesophageal varices, and to detect the best and most available non- invasive predictor for it. | 3 years |
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.

Official Title
-----------------
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fasting Conditions

Conditions
-----------------
Essential Hypertension

Intervention / Treatment
-----------------
* Drug: perindopril erbumine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to perindopril or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: perindopril erbumine|8 mg tablet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 20 Days |
Endoscopic Guided PCNL Versus Standard PCNL

Study Overview
=================
Brief Summary
-----------------
currently, percutaneous nephrolithotomy (PCNL) is the standard procedure of choice for management of large renal more than 2 cm. the pivotal step in performing PCNL is creation of proper tract. this step can be done monitored under guidance of different modalities such as fluoroscopy, ultrasonography, endoscopy or combined in ECIRS, tract creation is controlled under endoscopic vision with a flexible ureteroscope .

Detailed Description
-----------------
Aim: compare safety and efficacy and adverse events of ECIRS in comparison of standard fluoroscopic guided PCNL. patients & methods: Patients will randomly be divided into two equal groups: Group A: Patient will undergo ECIRS. Group B: Patient will undergo standard PCNL

Official Title
-----------------
Endoscopic Combined Intrarenal Surgery for Management of Large Renal Stones: A Randomized Controlled Trial

Conditions
-----------------
Stones, Kidney

Intervention / Treatment
-----------------
* Procedure: Endoscopic compbined guided PCNL
* Procedure: Standard PCNL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with renal stones diameter of at least 2 cm. American Society of Anesthesiology score ≤ 2. Exclusion Criteria: patients with renal anomalies. transplanted kidney. uncorrected coagulopathy. active infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ECIRS-Group<br> | Procedure: Endoscopic compbined guided PCNL<br>* patient undergo stone removal by ECIRS<br>|
| Active Comparator: SPCNL-GRoup<br> | Procedure: Standard PCNL<br>* patient undergo SPCNL<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stone Free Rate | If their is any residual stones | 1day after operation. | 
| Stone Free Rate | If their is any residual stones | 1 months post operative | 
| Stone Free Rate | If their is any residual stones | 3 months post-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| operative time | the length of operation | intra oprative | 
| blood loss | hemoglobin drop | pre-operative and 1 day post-oprative |
Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture

Study Overview
=================
Brief Summary
-----------------
Purpose: To assess long-term outcomes of implantation of black diaphragmintraocular lens (BD IOL) in postraumatic aniridia and aphakia due to eye rupture. METHODS: This is retrospective consecutive case series of 14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with. Measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions. The average postoperative follow-up period was 36 months.

Official Title
-----------------
Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture

Conditions
-----------------
Aphakia Due to Trauma, Eye; Rupture, Traumatic, With Loss of Intraocular Tissue, Aniridia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: post-traumatic complete aniridia and aphakia Exclusion Criteria: active ocluar inflammation or infection

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group of 14 patients with post-traumatic complete anirirdia<br>14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best-corrected visual acuity | The visual acuity measurement with ETDRS chart | 10 to 120 months | 
| The slit lamp examination | The anterior segment of the eye and eye fundus were examined. | 10 to 120 months | 
| The intrraocular pressure measurement | The procedure was performed with the Goldman applanation tonometer. | 10 to 120 months | 
| The medical history | Coexisting eye diseases and post-operative complications were noted. | 10 to 120 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aphakia, black diaphragmintraocular lens, eye rupture, aniridia
The Effects of Plant Bioactives on Platelet Function

Study Overview
=================
Brief Summary
-----------------
Consumption of a diet rich in fruit and vegetables is associated with a reduced risk of cardiovascular disease and the protective effect may be due to polyphenolic compounds contained within these foods. The mechanism by which polyphenols exert this effect is not clearly understood but research has focused on their potential to affect platelet function. The purpose of this study is to quantify the anti-clotting activity of a range of plant food extracts and component compounds.

Detailed Description
-----------------
A single sample of whole blood will be collected from 15 male or female volunteers aged between 18 and 65 years. After collection whole blood will be treated with a range of flavonoids to evaluate their effects on platelet function.

Official Title
-----------------
The Effects of Plant Bioactives on Platelet Function

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Ex-vivo treatments with flavonoids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females Aged 18 - 65 years. BMI > 19.5 and < 35 Non-smokers Exclusion Criteria: Pregnancy or have been pregnant within the last 12 months Parallel participation in another research project which involves dietary intervention Participation in another research project which has involved blood sampling within the last four months unless the total amount of combined blood from both studies does not exceed 470 mls. Has donated or intends to donate blood within 16 weeks prior to during the Study period. Depressed or elevated blood pressure measurements (<90/50 or 95/50 if symptomatic or >160/100) Any person related to or living with any member of the study team Diabetics Taking regular prescribed and/or non-prescribed medication (excluding oral contraceptive and HRT). Known bleeding disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ex-vivo treatment of platelets<br>Ex-vivo treatment of platelets | Other: Ex-vivo treatments with flavonoids<br>* Ex-vivo treatment of platelets with a range of flavonoids<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of flavonoids that exert a significant anti-clotting effect |  | within 4hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Flavonoids, Platelets
Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism

Study Overview
=================
Brief Summary
-----------------
To compare the effect of T4-T3 combination therapy versus T4 monotherapy in patients with autoimmune hypothyroidism, on stable T4-substitution therapy

Detailed Description
-----------------
double blind randomized cross-over study.

Official Title
-----------------
Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.

Conditions
-----------------
Quality of Life, Depression

Intervention / Treatment
-----------------
* Drug: Triiodothyronine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypothyroidism, S-TSH> 20 at diagnosis,Anti-TPO >300 Normal TSH (0,4-4,0) for 6 months. Exclusion Criteria: <18 år >75 år pregnant women Thyroid cancer T3 treatment Post-partum thyroiditis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>Usual T4 dose is given | |
| Active Comparator: 2<br>20 microgram of T3 is given and 50 microgram of T4 is withdrawn | Drug: Triiodothyronine<br>* 50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Selv-rating scales: SF-36, SCL -90-R, BDI |  | 3 month treating | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI, bioimpedance |  | 3 month treament | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypothyroidism, quality og life, depression
Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine whether fish oil (specifically omega-3 long chain polyunsaturated fatty acids [EPA-DHA]) supplementation can enhance eccentric resistance exercise performance when combined with a resistance exercise training study. The investigators aim to establish the potential mechanisms that might mediate performance changes at a cellular level.

Official Title
-----------------
Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance, Inflammation, Gene Expression and Epigenetic Signatures

Conditions
-----------------
Exercise-induced Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: Fish Oil
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males Healthy Exclusion Criteria: Resistance exercise training within the past 6 months Vitamin or fish oil supplementation over the past 6 months Habitual use of anti-inflammatory drugs History of heart disease History of coagulation/bleeding disorder History of metabolic disease Serious allergy Known to have blood-borne virus Females (Due to differences in cell membrane incorporation of Omega-3 between the sexes and the testing schedule being unable to fit in with menstrual cycle, altering the blood markers that are being measured) Currently no symptoms of general illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fish Oil<br>Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway | Dietary Supplement: Fish Oil<br>* Fish Oil Capsule<br>* Other names: n-3 PUFA, Omega-3;|
| Placebo Comparator: Placebo<br>Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway | Dietary Supplement: Placebo<br>* Olive Oil capsule manufactured to mimic fish oil capsule<br>* Other names: Olive Oil;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Strength | Quadriceps and Hamstring strength using an isokinetic dynamometer | Change from baseline strength at 11 weeks | 
| Leg power | Dynamic leg power assessed through jump height on force platform | Change from baseline strength at 11 weeks |